Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Cancer-selective targeting of the NF-κB pathway via GADD45β/MKK7 inhibition: Results from the phase I trial of the first-in-class inhibitor, DTP3, in patients with relapsed or refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

ACAristeidis ChaidosDPDimitrios PotolidisHAHolger W. Auner

Discussion

Loading...

Member takes

Overview

Phase I trial shows DTP3 results in apoptosis in patients with relapsed multiple myeloma, indicating a favorable safety profile.

Key Points

  • Evaluate the safety and preliminary efficacy of DTP3 in relapsed or refractory multiple myeloma.
  • Conducted a Phase I multi-centre dose-escalation trial
  • Administered DTP3 intravenously in 28-day cycles
  • Monitored pharmacokinetics and pharmacodynamics
  • Assessed adverse events and clinical responses according to established criteria
  • Observed a Very Good Partial Response in one patient at 30 mg/kg
  • Stable disease noted in 6 patients (46.15%)
  • Identified 45 mg/kg as the Maximum Tolerated Dose
  • Favorable pharmacokinetics observed with a median plasma half-life of 8.1 hours
  • Dysgeusia recorded as a common treatment-related adverse event

Cite This Study

Chaidos et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d177https://doi.org/10.1182/blood-2025-5825
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1GT919, a novel IKZF3/1 molecular glue degrader: Phase 1 safety and preliminary efficacy in relapsed or refractory multiple myeloma (R/R MM)2025
  2. 2Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL).2024 · 10 citations
  3. 3Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).2024
  4. 4Early rescue intervention with daratumumab, pomalidomide and dexamethasone (DPd) in high-risk smoldering myeloma (HR-SMM) patients included in the GEM-CESAR treated with carfilzomib, lenalidomide and dexamethasone (KRd)- autologous stem cell transplantation (ASCT)-krd-rd2025 · 2 citations
  5. 5A phase 2 trial of teclistamab plus daratumumab combination therapy for high-risk smoldering multiple myeloma: First pre-planned analysis (the REVIVE Study)2025